These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
219 related items for PubMed ID: 35263900
41. Anasarca: not a nephrotic syndrome but dermatomyositis. Zedan M, El-Ayouty M, Abdel-Hady H, Shouman B, El-Assmy M, Fouda A. Eur J Pediatr; 2008 Jul; 167(7):831-4. PubMed ID: 18414893 [Abstract] [Full Text] [Related]
42. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, Cintas HL, McGarvey CL, James-Newton L, Pokrovnichka A, Moini B, Cabalar I, Lovell DJ, Wesley R, Plotz PH, Miller FW, Hicks JE, Rider LG. Rheumatology (Oxford); 2009 Feb; 48(2):134-9. PubMed ID: 19074186 [Abstract] [Full Text] [Related]
43. How Often are Pediatric Patients with Clinically Amyopathic Dermatomyositis Truly Amyopathic? Oberle EJ, Bayer ML, Chiu YE, Co DO. Pediatr Dermatol; 2017 Jan; 34(1):50-57. PubMed ID: 27813167 [Abstract] [Full Text] [Related]
44. Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center's experience. Patwardhan A, Rennebohm R, Dvorchik I, Spencer CH. Pediatr Rheumatol Online J; 2012 Sep 20; 10(1):34. PubMed ID: 22995763 [Abstract] [Full Text] [Related]
45. [Clinical characteristics of juvenile dermatomyositis complicated with interstitial lung disease]. Chen L, Hu Y, Yao Y, Zhen XF, Chen F, He Q, Mo X, Ma SC. Zhonghua Er Ke Za Zhi; 2012 Jun 20; 50(6):465-9. PubMed ID: 22931947 [Abstract] [Full Text] [Related]
46. Long-term outcome in patients with juvenile dermatomyositis: A case series. Chevalier G, Fakih O, Lhose A, Ballot-Schmit C, Prati C, Puzenat E, Aubin F. Arch Pediatr; 2021 Aug 20; 28(6):475-479. PubMed ID: 34034928 [Abstract] [Full Text] [Related]
47. Juvenile dermatomyositis in South African children is characterised by frequent dystropic calcification: a cross sectional study. Faller G, Mistry BJ, Tikly M. Pediatr Rheumatol Online J; 2014 Jan 07; 12():2. PubMed ID: 24397895 [Abstract] [Full Text] [Related]
48. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, Miller FW, Rider LG, with the Childhood Myositis Heterogeneity Collaborative Study Group. Medicine (Baltimore); 2013 Jan 07; 92(1):25-41. PubMed ID: 23263716 [Abstract] [Full Text] [Related]
49. Rapid and sustained response to JAK inhibition in a child with severe MDA5 + juvenile dermatomyositis. Strauss T, Günther C, Schnabel A, Wolf C, Hahn G, Lee-Kirsch MA, Brück N. Pediatr Rheumatol Online J; 2023 Sep 19; 21(1):104. PubMed ID: 37726751 [Abstract] [Full Text] [Related]
50. Clinical analysis of 50 children with juvenile dermatomyositis. Kishi T, Miyamae T, Hara R, Nakajima S, Imagawa T, Mori M, Yokota S. Mod Rheumatol; 2013 Mar 19; 23(2):311-7. PubMed ID: 22526832 [Abstract] [Full Text] [Related]
51. Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children. Wang X, Ding Y, Zhou Z, Hou J, Xu Y, Li J. Pediatr Rheumatol Online J; 2021 Jan 06; 19(1):6. PubMed ID: 33407621 [Abstract] [Full Text] [Related]
52. Comparison of clinical and laboratory features and treatment responses in patients with clinically amyopathic juvenile dermatomyositis and classical juvenile dermatomyositis. Gezgin Yıldırım D, Baglan E, Güngörer V, Yıldız C, Tuncez S, Bülbül M, Acar B, Bakkaloğlu SA. Int J Rheum Dis; 2023 Aug 06; 26(8):1504-1511. PubMed ID: 37288472 [Abstract] [Full Text] [Related]
53. Myositis-specific autoantibodies and their associated phenotypes in juvenile dermatomyositis: data from a German cohort. Horn S, Minden K, Speth F, Schwarz T, Dressler F, Grösch N, Haas JP, Hinze C, Horneff G, Hospach A, Kallinich T, Klotsche J, Köstner K, Meisel C, Niewerth M, Oommen PT, Schütz C, Weller-Heinemann F, Unterwalder N, Sengler C. Clin Exp Rheumatol; 2022 Feb 06; 40(2):433-442. PubMed ID: 33124555 [Abstract] [Full Text] [Related]
54. Recent research on myositis-specific autoantibodies in juvenile dermatomyositis. He L. Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct 15; 23(10):1064-1068. PubMed ID: 34719424 [Abstract] [Full Text] [Related]
55. Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients. Mathiesen PR, Buchvald F, Nielsen KG, Herlin T, Friis T, Nielsen S. Rheumatology (Oxford); 2014 Apr 15; 53(4):644-9. PubMed ID: 24310298 [Abstract] [Full Text] [Related]
57. A fatal presentation of dermatomyositis with facial swelling. Dwivedi N, Michael C, Lew DB, Arnold S, Igarashi M, Bertorini T, Thompson JW, Myers LK, Brown ML. Int J Pediatr Otorhinolaryngol; 2012 May 15; 76(5):745-9. PubMed ID: 22376996 [Abstract] [Full Text] [Related]
58. Juvenile dermatomyositis with IgA nephropathy: case-based review. Mantoo MR, Tripathy SK, Phulware RH, Bagri NK, Hari P, Barwad A. Rheumatol Int; 2019 Mar 15; 39(3):577-581. PubMed ID: 30552457 [Abstract] [Full Text] [Related]
59. Clinical features and disease course of patients with juvenile dermatomyositis. Gowdie PJ, Allen RC, Kornberg AJ, Akikusa JD. Int J Rheum Dis; 2013 Oct 15; 16(5):561-7. PubMed ID: 24164844 [Abstract] [Full Text] [Related]
60. [Juvenile-onset anti-nuclear matrix protein 2 (NXP-2) antibody-positive dermatomyositis with joint contractures before manifestation of myositis: a case report]. Miura E, Taneda T, Umeda Y, Umeda M, Oyake M, Matsushita T, Nishino I, Fujita N. Rinsho Shinkeigaku; 2024 Jun 27; 64(6):417-421. PubMed ID: 38797685 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]